Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.

被引：0
|
作者：
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Cent Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Melanoma Inst Australia, Sydney, NSW, Australia
[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[4] Westmead Hosp, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[5] Blacktown Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Royal North Shore Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Royal North Shore Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [22] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
    Patel, Sandip P.
    Cano-Linson, Eleanor
    Chae, Young Kwang
    Schokrpur, Shiruyeh
    Lao, Christopher D.
    Powers, Benjamin C.
    Victor, Adrienne I.
    Onitilo, Adedayo A.
    Shin, Sarah
    Takebe, Naoko
    Threlkel, Sara
    Mcleod, Christine M.
    Chen, Helen X.
    Sharon, Elad
    Othus, Megan
    Ryan, Christopher W.
    Blanke, Charles D.
    Kurzrock, Razelle
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [23] Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
    Lee, Hansol
    Ferguson, Angela L.
    Quek, Camelia
    Vergara, Ismael A.
    daSilva, Ines Pires
    Allen, Ruth
    Gide, Tuba Nur
    Conway, Jordan W.
    Koufariotis, Lambros T.
    Hayward, Nicholas K.
    Waddell, Nicola
    Carlino, Matteo S.
    Menzies, Alexander M.
    Saw, Robyn P. M.
    Shklovskaya, Elena
    Rizos, Helen
    Lo, Serigne
    Scolyer, Richard A.
    V. Long, Georgina
    Palendira, Umaimaintha
    Wilmott, James S.
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2513 - 2524
  • [24] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [25] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Wagner, Nikolaus B.
    Forschner, Andrea
    Leiter, Ulrike
    Garbe, Claus
    Eigentler, Thomas K.
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 339 - 346
  • [26] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Nikolaus B Wagner
    Andrea Forschner
    Ulrike Leiter
    Claus Garbe
    Thomas K Eigentler
    British Journal of Cancer, 2018, 119 : 339 - 346
  • [27] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [28] Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
    Hassel, Jessica C.
    Heinzerling, Lucie
    Aberle, Jens
    Baehr, Oliver
    Eigentler, Thomas K.
    Grimm, Marc-Oliver
    Gruenwald, Victor
    Leipe, Jan
    Reinmuth, Niels
    Tietze, Julia K.
    Trojan, Joerg
    Zimmer, Lisa
    Gutzmer, Ralf
    CANCER TREATMENT REVIEWS, 2017, 57 : 36 - 49
  • [29] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [30] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345